Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

The M&A trend is a reversal from recent years, when high-flying valuations and more free-flowing investments allowed smaller biotech firms and startups to rebuff Big Pharma entreaties.

As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and ...

So far this year, seven major pharma companies have licensed or acquired molecules for new drugs originating from China, spending a total of at least $3.15 billion in upfront cash and equity ...

President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to helm the Department of Health and Human Services(HHS) ...

The cost of producing a medicine generally doesn't vary much — so it stands to reason that the US's big pharmaceutical companies should therefore earn far more in the US than they earn elsewhere.

Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, and investment overseas.

The phrase “big pharma” is often used to describe large pharmaceutical companies. Johnson & Johnson (JNJ 0.29%) and Pfizer (PFE-0.17%) rank as two of the largest of today’s big pharma companies.

The world's top pharmaceutical companies tap this group of consultants to provide AI-driven intelligence to get drugs to market faster. Behind big pharma is big intelligence Skip to main content ...

Yes, notwithstanding those costs, Big Pharma can ultimately profit and handsomely when a drug makes it through the FDA's approval process. In 2022, for instance, 57% of Pfizer's revenue came from ...

How AI and robotics are reshaping pharmaceutical R&D—from automated labs and in silico drug design to the growing tensions ...